160 related articles for article (PubMed ID: 22893048)
1. [Excess mortality and prolongation of stay due to bloodstream infections caused by multiresistant pathogens in Germany].
Gastmeier P; Schwab F; Meyer E; Geffers C
Dtsch Med Wochenschr; 2012 Aug; 137(34-35):1689-92. PubMed ID: 22893048
[TBL] [Abstract][Full Text] [Related]
2. Clinical and economic analysis of methicillin-susceptible and -resistant Staphylococcus aureus infections.
Kopp BJ; Nix DE; Armstrong EP
Ann Pharmacother; 2004 Sep; 38(9):1377-82. PubMed ID: 15266044
[TBL] [Abstract][Full Text] [Related]
3. Risk factors for and outcomes of bloodstream infection caused by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species in children.
Zaoutis TE; Goyal M; Chu JH; Coffin SE; Bell LM; Nachamkin I; McGowan KL; Bilker WB; Lautenbach E
Pediatrics; 2005 Apr; 115(4):942-9. PubMed ID: 15805368
[TBL] [Abstract][Full Text] [Related]
4. Mortality and hospital stay associated with resistant Staphylococcus aureus and Escherichia coli bacteremia: estimating the burden of antibiotic resistance in Europe.
de Kraker ME; Davey PG; Grundmann H;
PLoS Med; 2011 Oct; 8(10):e1001104. PubMed ID: 22022233
[TBL] [Abstract][Full Text] [Related]
5. Cost of bacteraemia caused by methicillin-resistant vs. methicillin-susceptible Staphylococcus aureus in Spain: a retrospective cohort study.
Rubio-Terrés C; Garau J; Grau S; Martinez-Martinez L;
Clin Microbiol Infect; 2010 Jun; 16(6):722-8. PubMed ID: 19712112
[TBL] [Abstract][Full Text] [Related]
6. The health and economic burden of bloodstream infections caused by antimicrobial-susceptible and non-susceptible Enterobacteriaceae and Staphylococcus aureus in European hospitals, 2010 and 2011: a multicentre retrospective cohort study.
Stewardson AJ; Allignol A; Beyersmann J; Graves N; Schumacher M; Meyer R; Tacconelli E; De Angelis G; Farina C; Pezzoli F; Bertrand X; Gbaguidi-Haore H; Edgeworth J; Tosas O; Martinez JA; Ayala-Blanco MP; Pan A; Zoncada A; Marwick CA; Nathwani D; Seifert H; Hos N; Hagel S; Pletz M; Harbarth S;
Euro Surveill; 2016 Aug; 21(33):. PubMed ID: 27562950
[TBL] [Abstract][Full Text] [Related]
7. A matched prospective cohort study on Staphylococcus aureus and Escherichia coli bloodstream infections: extended perspectives beyond resistance.
Berger J; Diab-Elschahawi M; Blacky A; Pernicka E; Spertini V; Assadian O; Koller W; Aichberger KJ
Am J Infect Control; 2010 Dec; 38(10):839-45. PubMed ID: 20650546
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of risk factors for the acquisition of bloodstream infections with extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species in the intensive care unit; antibiotic management and clinical outcome.
Cordery RJ; Roberts CH; Cooper SJ; Bellinghan G; Shetty N
J Hosp Infect; 2008 Feb; 68(2):108-15. PubMed ID: 18063198
[TBL] [Abstract][Full Text] [Related]
9. Risk factors for bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli.
Wu UI; Yang CS; Chen WC; Chen YC; Chang SC
J Microbiol Immunol Infect; 2010 Aug; 43(4):310-6. PubMed ID: 20688291
[TBL] [Abstract][Full Text] [Related]
10. Cost of the meticillin-resistant Staphylococcus aureus search and destroy policy in a Dutch university hospital.
Nulens E; Broex E; Ament A; Deurenberg RH; Smeets E; Scheres J; van Tiel FH; Gordts B; Stobberingh EE
J Hosp Infect; 2008 Apr; 68(4):301-7. PubMed ID: 18353496
[TBL] [Abstract][Full Text] [Related]
11. Bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy.
Kang CI; Kim SH; Park WB; Lee KD; Kim HB; Kim EC; Oh MD; Choe KW
Antimicrob Agents Chemother; 2004 Dec; 48(12):4574-81. PubMed ID: 15561828
[TBL] [Abstract][Full Text] [Related]
12. Extended-spectrum beta-lactamase-producing phenotype signifies a poor prognosis for patients with cefpodoxime-resistant Escherichia coli or Klebsiella pneumoniae bacteremia.
Lee CI; Lee NY; Yan JJ; Lee HC; Ko NY; Chang CM; Wu CJ; Chen PL; Wang LR; Ko WC
J Microbiol Immunol Infect; 2009 Aug; 42(4):303-9. PubMed ID: 19949753
[TBL] [Abstract][Full Text] [Related]
13. Clinical and economic impact of methicillin resistance in patients with Staphylococcus aureus bacteremia.
Lodise TP; McKinnon PS
Diagn Microbiol Infect Dis; 2005 Jun; 52(2):113-22. PubMed ID: 15964499
[TBL] [Abstract][Full Text] [Related]
14. [Which rate describes the MRSA situation appropriately?].
Gastmeier P; Chaberny IF
Dtsch Med Wochenschr; 2007 Jul; 132(27):1480-2. PubMed ID: 17583833
[TBL] [Abstract][Full Text] [Related]
15. Burden of antimicrobial resistance in European hospitals: excess mortality and length of hospital stay associated with bloodstream infections due to Escherichia coli resistant to third-generation cephalosporins.
de Kraker ME; Wolkewitz M; Davey PG; Koller W; Berger J; Nagler J; Icket C; Kalenic S; Horvatic J; Seifert H; Kaasch A; Paniara O; Argyropoulou A; Bompola M; Smyth E; Skally M; Raglio A; Dumpis U; Melbarde Kelmere A; Borg M; Xuereb D; Ghita MC; Noble M; Kolman J; Grabljevec S; Turner D; Lansbury L; Grundmann H
J Antimicrob Chemother; 2011 Feb; 66(2):398-407. PubMed ID: 21106563
[TBL] [Abstract][Full Text] [Related]
16. Outcomes and costs associated with a history of vancomycin exposure in patients with MRSA-related complicated bacteremia and infective endocarditis.
Brown J; Brown KA; Forrest A
Clin Ther; 2011 Oct; 33(10):1475-82. PubMed ID: 21925733
[TBL] [Abstract][Full Text] [Related]
17. Staphylococcus aureus bloodstream infections: risk factors, outcomes, and the influence of methicillin resistance in Calgary, Canada, 2000-2006.
Laupland KB; Ross T; Gregson DB
J Infect Dis; 2008 Aug; 198(3):336-43. PubMed ID: 18522502
[TBL] [Abstract][Full Text] [Related]
18. Nephrotoxicity of vancomycin in patients with methicillin-resistant Staphylococcus aureus bacteraemia.
Shen WC; Chiang YC; Chen HY; Chen TH; Yu FL; Tang CH; Sue YM
Nephrology (Carlton); 2011 Nov; 16(8):697-703. PubMed ID: 21707841
[TBL] [Abstract][Full Text] [Related]
19. Risk factors for infection and treatment outcome of extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae bacteremia in patients with hematologic malignancy.
Kang CI; Chung DR; Ko KS; Peck KR; Song JH;
Ann Hematol; 2012 Jan; 91(1):115-21. PubMed ID: 21556875
[TBL] [Abstract][Full Text] [Related]
20. Future strategies for treating Staphylococcus aureus bloodstream infections.
Naber CK
Clin Microbiol Infect; 2008 Mar; 14 Suppl 2():26-34. PubMed ID: 18226087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
